Vivus (VVUS) urges shareholders to re-elect the current board, arguing that First Manhattan's...


Vivus (VVUS) urges shareholders to re-elect the current board, arguing that First Manhattan's plan for the company is "woefully short on details" and contains the same ideas Vivus is already implementing. First Manhattan says that former AstraZeneca exec Anthony Zook has agreed to be Vivus CEO if the activist investor prevails in the shareholder vote in just under two weeks. The cause of Vivus' current management can't have been helped by an NYT article profiling the failure of the firm's Qsymia weight-loss drug to take off since its launch in September.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs